ScreenerHero

URGNUroGen Pharma Ltd.

NAS · US · Healthcare · Biotechnology · urogen.com
46.86USD-6.82%Mkt Cap: 2.29B $P/E: —

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse therm…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.29B $
Enterprise Value2.38B $
Revenue (TTM)188.73M $
Gross Profit97.34M $
Net Income (TTM)-153.49M $
Revenue/Share3.815 USD
Last Price46.86 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees300
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)16.75
PEG—
EV/EBITDA-35.81
EV/Revenue12.59
P/S12.12
P/B-17.28
EPS (TTM)-1.83
EPS (Forward)2.79
52W Range
15.8689% of range50.81
52W High50.81 USD
52W Low15.86 USD
Profitability
Gross Margin88.66%
Oper. Margin0.15%
EBITDA Margin-35.15%
Profit Margin-139.81%
ROE145.53%
ROA-76.57%
Growth
Revenue Growth199.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.44M $
CapEx (TTM)289.00K $
FCF Margin-56.68%
FCF Yield-4.67%
Net Debt88.15M $
Net Debt/EBITDA-1.33
Balance Sheet
Debt/Equity-1.22
Current Ratio3.80
Quick Ratio3.18
Book Value/Sh-2.7090 USD
Cash/Share2.209 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)60.00 USD
Upside (mean)+28.0%
Target Range48.00 USD – 75.00 USD
$48.00+28.0% to mean$75.00
# Analysts8
Ownership
Shares Out.48.88M
Float43.35M
Insiders3.60%
Institutions93.19%
Short Interest
Short Ratio6.0d
Short % Float9.61%
Short % Out.9.42%
Shares Short4.59M
Short (prev mo.)6.22M
Technical
SMA 5039.89 (+17.5%)
SMA 20027.05 (+73.2%)
Beta1.57
S&P 52W Chg18.16%
Avg Vol (30d)883.41K
Avg Vol (10d)1.11M
Technical Indicators
RSI (14)59.0
MACD2.8271
MACD Signal2.6867
MACD Hist.+0.1403
BB Upper52.23 USD
BB Middle44.41 USD
BB Lower36.58 USD
BB Width35.23%
ATR (14)2.402 USD
Vol Ratio (20d)0.81x